(NASDAQ: TMDX) Transmedics Group's forecast annual revenue growth rate of 18.02% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Transmedics Group's revenue in 2025 is $488,227,000.On average, 5 Wall Street analysts forecast TMDX's revenue for 2025 to be $19,636,047,874, with the lowest TMDX revenue forecast at $19,497,397,011, and the highest TMDX revenue forecast at $19,698,031,374. On average, 5 Wall Street analysts forecast TMDX's revenue for 2026 to be $23,703,342,865, with the lowest TMDX revenue forecast at $23,548,993,124, and the highest TMDX revenue forecast at $23,786,167,978.
In 2027, TMDX is forecast to generate $26,947,833,965 in revenue, with the lowest revenue forecast at $26,170,773,356 and the highest revenue forecast at $27,516,681,443.